# Changes in apolipoproteins following ingestion of a beverage delivering β-hydroxybutyrate: results from a randomized placebo-controlled trial

**Authors:** Yutong Liu, Wandia Kimita, Sakina H. Bharmal, Maxim S. Petrov

PMC · DOI: 10.3389/fnut.2025.1726174 · Frontiers in Nutrition · 2026-02-05

## TL;DR

A study found that a ketone supplement increased a specific apolipoprotein linked to fat metabolism, especially in people with high triglycerides.

## Contribution

This is the first study to show that KEβHB affects apo C-II and apo B in individuals with hypertriglyceridemia.

## Key findings

- KEβHB increased apo C-II levels significantly compared to placebo.
- In hypertriglyceridemic individuals, KEβHB reduced apo B levels.
- No significant changes were observed in other apolipoproteins overall.

## Abstract

Apolipoproteins play important roles in the metabolism of triglyceride-rich lipoproteins. Ketone monoester β-hydroxybutyrate (KEβHB) has been shown to reduce the circulating levels of remnant cholesterol and triglycerides. However, the mechanisms behind this action remain unknown.

To investigate the effect of KEβHB supplementation on apolipoproteins and to study whether circulating levels of triglycerides play a role in this effect.

The study was a randomized placebo-controlled trial, registered at https://www.clinicaltrials.gov/ (NCT03889210). It included 18 adults (12 men and 6 women) with prediabetes (defined as per the American Diabetes Association criteria). Following an overnight fast, participants ingested a KEβHB or a placebo beverage in a cross-over manner. Serial blood samples were collected from baseline to 150 min at intervals of 30 min. The endpoints were changes in apolipoprotein (apo) A-I, apo B, apo B-48, apo C-II, apo C-III, and apo E. Area under the curve (AUC) analyses were calculated to estimate changes in the studied apolipoproteins over time. Participants were further stratified into ‘hypertriglyceridemia’ and normal triglyceride levels subgroups.

Ingestion of the KEβHB beverage led to a significantly higher AUC for apo C-II (p = 0.023) in the overall cohort. No statistically significant differences in AUCs were found for the other studied apolipoproteins. The subgroup analysis showed significantly lower levels of apo B (and higher levels of apo C-II) after the KEβHB beverage in individuals with hypertriglyceridemia only. No significant associations were found for the other studied apolipoproteins in either subgroup.

Exogenously induced acute ketosis resulted in a significantly elevated apo C-II compared with the placebo. Further, the levels of apo B were significantly lowered following ingestion of the KEβHB beverage only among individuals with hypertriglyceridemia. Acute nutritional ketosis may be considered as a potential approach to reduce atherogenic triglyceride-rich lipoproteins in individuals at high cardiovascular disease risk.

## Linked entities

- **Chemicals:** β-hydroxybutyrate (PubChem CID 92135)
- **Diseases:** prediabetes (MONDO:0006920), hypertriglyceridemia (MONDO:0005347), cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, AOPEP (aminopeptidase O (putative)) [NCBI Gene 84909] {aka AP-O, APO, C90RF3, C9orf3, DYT31, ONPEP}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, APOC3 (apolipoprotein C3) [NCBI Gene 345] {aka APOCIII, Apo-C3, ApoC-3}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}, APOC2 (apolipoprotein C2) [NCBI Gene 344] {aka APO-CII, APOC-II}
- **Diseases:** Acute ketosis (MESH:D007662), LPL deficiency (MESH:D008072), Hypertriglyceridemia (MESH:D015228), death (MESH:D003643), atherogenic (MESH:D050197), CVD (MESH:D002318), metabolic disorders (MESH:D008659), TRL (MESH:C566031), inflammation (MESH:D007249), Dyslipidemia (MESH:D050171), Diabetes (MESH:D003920), malignancy (MESH:D009369), prediabetes (MESH:D011236)
- **Chemicals:** lipid (MESH:D008055), alcohol (MESH:D000438), glucose (MESH:D005947), KEbetaHB (-), carbohydrates (MESH:D002241), phospholipids (MESH:D010743), water (MESH:D014867), free fatty acids (MESH:D005230), cholesterol (MESH:D002784), malic acid (MESH:C030298), beta-hydroxybUtyrate (MESH:D020155), EDTA (MESH:D004492), triglyceride (MESH:D014280), ketone (MESH:D007659)
- **Species:** Stevia (genus) [taxon 55669], Felis catus (cat, species) [taxon 9685], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916354/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12916354/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916354/full.md

---
Source: https://tomesphere.com/paper/PMC12916354